Evaluation of nuclear NF-κB, transglutaminase2, and ERCC1 as predictors of platinum resistance in testicular tumors

Azambuja, Alan A; Engroff, Paula; Silva, Bruna T; Zorzetti, Roberta C. S; Morrone, Fernanda B.
Int. braz. j. urol ; 46(3): 353-362, May-June 2020. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1090612

Documentos relacionados

  1. Evaluation of nuclear NF-κB, transglutaminase2, and ERCC1 as predictors of platinum resistance in testicular tumors.
  2. NF-κB targeting for overcoming tumor resistance and normal tissues toxicity.
  3. Interference between copper transport systems and platinum drugs.
  4. Cancer Antigen 125 Expression Enhances the Gemcitabine/Cisplatin-Resistant Tumor Microenvironment in Bladder Cancer.
  5. p53 and MDM2 expression in primary and metastatic testicular germ cell tumors: Association with clinical outcome.
  6. EZH2 regulates expression of FOXC1 by mediating H3K27me3 in breast cancers.
  7. Circ_0001658 regulates gefitinib resistance of non-small cell lung cancer through miR-409-3p/TWIST1 axis.
  8. KDM5 demethylases and their role in cancer cell chemoresistance.
  9. MYC-Mediated Ribosomal Gene Expression Sensitizes Enzalutamide-resistant Prostate Cancer Cells to EP300/CREBBP Inhibitors.
  10. LncRNA-MALAT1 mediates cisplatin resistance via miR-101-3p/VEGF-C pathway in bladder cancer.